Christopher A. Kuebler, Director at NEKTAR THERAPEUTICS (NKTR), sold 15,000 shares at $16.00 ($240K) on 2015-01-13, disclosed to the SEC on 2015-01-15.
Scheduled sale ($240k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| WAT | SELL | 2023-08-07 | $1.2M | — | Filing → |
| WAT | SELL | 2022-05-23 | $1.3M | — | Filing → |
| WAT | SELL | 2021-08-19 | $1.2M | — | Filing → |